Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2009 Mar 1;199(5):610-2.
doi: 10.1086/596737.

Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options

Robert W Shafer
Editorial

Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options

Robert W Shafer. J Infect Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: R.W.S. has consulted for Bristol-Myers Squibb, Celera, and Siemens Health Care. He has received speaking honoraria from Gilead Sciences and research funding from Abbott Laboratories, Bristol Myers Squibb, Celera, and Gilead Sciences. He has an ongoing research collaboration with 454 Life Sciences–Roche Diagnostics.

Comment on

References

    1. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr. 2006;42:610–3. - PubMed
    1. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A. 2006;103:7094–9. - PMC - PubMed
    1. Cai F, Chen H, Hicks CB, Bartlett JA, Zhu J, Gao F. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods. 2007;4:123–5. - PubMed
    1. Beck IA, Crowell C, Kittoe R, et al. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr. 2008;48:418–27. - PMC - PubMed
    1. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5:e158. - PMC - PubMed

Substances